// App-Quantinova.ai

P198 : An inflammatory serum metabolomic signature predicts response to vedolizumab treatment in people with Crohn’s Disease

Researchers

Presenter

  • Radford-Smith, D

Principal Investigators

  • Yates, A

  • Hageman, I

  • Joustra, V

  • Li Yim, A

  • Davids, M

  • Henneman, P

  • Hakvoort, T

  • D'Haens, G

  • de Jong, W

  • Anthony, D

  • Satsangi, J

  • Probert, F

Medical Centers

  • University of Oxford, Department of Oncology, Oxford, United Kingdom

  • University of Oxford, Department of Oncology, Oxford, United Kingdom

  • Amsterdam UMC- University of Amsterdam, Genome Diagnostics Laboratory- Department of Human Genetics, Amsterdam, The Netherlands

  • Academic Medical Center, Laboratory of Experimental Vascular Medicine, Amsterdam, The Netherlands

  • Academic Medical Center AMC University of Amsterdam, Tytgat Institute for Liver and Intestinal Research, Amsterdam, The Netherlands

  • University of Oxford, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom

Locations

  • United Kingdom

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Crohn's disease

Biomarkers

  • C reactive protein

  • Faecal calprotectin

Drug/Treatment

  • Entyvio

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved